Preventing thromboembolic complications in older orthopaedic surgery patients. Interventions and outcomes

Drugs and Aging

Volumn 15, Issue 4, 1999, Pages 297-306

  Eikelboom, John W ^a   Ginsberg, Jeffrey S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN;

ADULT; AGED; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HIP SURGERY; HUMAN; KNEE SURGERY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGING; FIBRINOLYTIC AGENTS; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; THROMBOEMBOLISM;

EID: 0032728011     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915040-00005     Document Type: Review

References (56)

1. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998 Mar 23; 158 (6): 585-93
2. Anderson Jr FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991 May; 151 (5): 933-8
3. Dalen JE, Alpert JS, Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975 Jan-Feb; 17 (4): 257-70
4. Sandler DA, Martin JF, Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989 Apr; 82 (4): 203-5
5. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996 Jul 1; 125 (1): 1-7
6. Brandjes DP, Buller HR, Heijboer H. et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997 Mar 15; 349 (9054): 759-62
7. Clagett GP, Anderson Jr FA, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998 Nov; 114 (5 Suppl.): 531S-60
8. Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty: Canadian Collaborative Group. Arch Intern Med 1998 Apr 27; 158 (8): 873-8
9. Robinson KS, Anderson DR, Gross M, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study: a randomized, controlled trial. Ann Intern Med 1997 Sep 15; 127 (6): 439-45
10. Madhok R, Lewallen DG, Wallrichs SL, et al. Trends in the utilization of primary total hip arthroplasty, 1969 through 1990: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 1993 Jan; 68 (1): 11-8
11. Quam JP, Michel Jr CJ, Wilson MG, et al. Total knee arthroplasty: a population-based study. Mayo Clin Proc 1991 Jun; 66 (6): 589-95
12. Seagroatt V, Tan HS, Goldacre M, et al. Elective total hip replacement: incidence, emergency readmission rate, and post-operative mortality. BMJ 1991 Dec 7; 303 (6815): 1431-5
13. Rajaratnam G, Black NA, Dalziel M. Total hip replacements in the National Health Service: is need being met? J Pub Health Med 1990 Feb; 12 (1): 56-9
14. Siddique RM, Siddique MI, Connors Jr AF, et al. Thirty-day case-fatality rates for pulmonary embolism in the elderly. Arch Intern Med 1996 Nov 11; 156 (20): 2343-7
15. Mari D, Mannucci PM, Coppola R, et al. Hypercoagulability in centenarians: the paradox of successful aging. Blood 1995 Jun 1; 85 (11): 3144-9
16. Tracy RP, Bovill EG, Fried LP, et al. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years: results from the Cardiovascular Health Study. Ann Epidemiol 1992 Jul; 2 (4): 509-19
17. Nurmohamed MT, Buller HR. ten Cate JW. Physiological changes due to age: implications for the prevention and treatment of thrombosis in older patients. Drugs Aging 1994 Jul; 5 (1): 20-33
18. Schina Jr MJ, Neumyer MM, Healy DA, et al. Influence of age on venous physiologic parameters. J Vasc Surg 1993 Nov; 18 (5): 749-52
19. Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994 Dec 15; 331 (24): 1630-41
20. Lohr JM, James KV, Deshmukh RM, et al. Allastair B. Karmody Award: calf vein thrombi are not a benign finding. Am J Surg 1995 Aug; 170 (2): 86-90
21. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985 Sep 7; 11 (8454): 515-8
22. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981 Apr; 94 (4 Pt 1):439-44
23. Parmet JL, Berman AT, Horrow JC, et al. Thromboembolism coincident with tourniquet deflation during toted knee arthroplasty. Lancet 1993 Apr 24; 341 (8852): 1057-8
24. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996 Jul 27; 348 (9022): 224-8
25. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996 Sep 5; 335 (10): 696-700
26. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin. Thromb Haemost 1997 Jan; 77 (1): 26-31
27. Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990 May 2; 263 (17): 2335-40
28. Prins MH, Hirsh J. A comparison of general and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. Thromb Haemost 1990 Dec 28; 64 (4): 497-500
29. Nicolaides AN, Bergqvist D, Hull R, et al. Prevention of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). Int Angiol 1997 Mar; 16 (1): 3-38
30. Guyatt GH, Cook DJ, Sackett DL, et al. Grades of recommendation for antithrombotic agents. Chest 1998 Nov; 114 (5 Suppl.): 441S-4
31. Perez JV, Warwick DJ, Case CP, et al. Death after proximal femoral fracture: an autopsy study. Injury 1995 May; 26 (4): 237-40
32. Todd CJ, Freeman CJ, Camilleri-Ferrante C, et al. Differences in mortality after fracture of hip: the cast Anglian audit. BMJ 1995 Apr 8; 310 (6984): 904-8
33. Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism: a meta-analysis. Arch Intern Med 1994 Jan 10; 154 (1): 67-72
34. Westrich GH, Sculce TP. Prophylaxis against deep vein thrombosis after total knee arthroplasty: pneumatic plantar compression and aspirin compared with aspirin alone. J Bone Joint Surg Am 1996 Jun; 78 (6): 826-34
35. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994 Jan 22; 308 (6923); 235-46
36. Collins R, Baigent C, Sandercock P, et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. BMJ 1994 Nov 5; 309 (6963): 1215-7
37. Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop 1996 Mar; (324): 251-8
38. Graor RA, Stewart JH, Lotke PA, et al. RD heparin (ardeparin sodium) vs aspirin to prevent deep vein thrombosis after hip or knee replacement surgery [abstract]. Chest 1992 Aug; 102 (2 Suppl.): 118S
39. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 1983 Oct 20; 309 (16): 954-8
40. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992; 111 (2): 110-20
41. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989; 19(1): 5-12
42. Hull RD, Raskob GE, Pineo GF, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993 Nov 4; 329 (19): 1370-6
43. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994 Aug; 76 (8): 1174-85
44. Francis CW, Pellegrini Jr VD, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997 Sep; 79 (9): 1365-72
45. Mohr DN, Silverstein MD, Murtaugh PA, et al. Prophylactic agents for deep vein thrombosis in elective hip surgery. Arch Intern Med 1993 Oct 11; 153 (19): 2221-8
46. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994 Jun 8; 271 (22): 1780-5
47. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery; a double-blind, dose-ranging study: Ardcparin Anthroplasty Study Group. Thromh Haemost 1997 Jan; 77 (1): 32-8
48. Spiro TE, Fitzgerald RH, Trowbridge AA, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery: enoxaparin Clinical Trial Group. Ann Intern Med 1994 Jul 15; 121 (2): 81-9
49. Leclere JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996 Apr 1: 124 (7): 619-26
50. Eriksson BI, Ekman S, Kalebo P, et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996 Mar 9; 347 (9002): 635-9
51. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997 Mar; 79 (3): 326-33
52. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997 Nov 6; 337 (19): 1329-35
53. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994 Nov; 90 (5): 2385-9
54. Hull RD, Brant RF, Pinto GF, et al. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999; 159: 137-41
55. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg 1997 Oct; 85 (4): 874-85
56. Hirsh J. Evidence for the needs of out-of-hospital thrombosis prophylaxis: introduction. Chest 1998 Aug; 114 (2 Suppl.): 113S-14